gamma-aminobutyric acid has been researched along with Dyskinesia, Drug-Induced in 142 studies
gamma-Aminobutyric Acid: The most common inhibitory neurotransmitter in the central nervous system.
gamma-aminobutyric acid : A gamma-amino acid that is butanoic acid with the amino substituent located at C-4.
Dyskinesia, Drug-Induced: Abnormal movements, including HYPERKINESIS; HYPOKINESIA; TREMOR; and DYSTONIA, associated with the use of certain medications or drugs. Muscles of the face, trunk, neck, and extremities are most commonly affected. Tardive dyskinesia refers to abnormal hyperkinetic movements of the muscles of the face, tongue, and neck associated with the use of neuroleptic agents (see ANTIPSYCHOTIC AGENTS). (Adams et al., Principles of Neurology, 6th ed, p1199)
| Excerpt | Relevance | Reference |
|---|---|---|
| "We have observed two cases of chlorpromazine-induced neuroleptic malignant syndrome (NMS); both were transiently responsive to intravenous diazepam challenge, but not to blind placebo or amyobarbitol." | 9.05 | Chlorpromazine-induced neuroleptic malignant syndrome and its response to diazepam. ( Lew, TY; Tollefson, G, 1983) |
| "Vigabatrin was specifically designed to enhance gamma-aminobutyric acid (GABA) function in the CNS." | 7.77 | Vigabatrin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in epilepsy and disorders of motor control. ( Grant, SM; Heel, RC, 1991) |
| " I report a patient who developed the syndrome during treatment for schizophrenia with the antipsychotic agent molindone hydrochloride." | 7.68 | Neuroleptic-induced "painful legs and moving toes" syndrome: successful treatment with clonazepam and baclofen. ( Sandyk, R, 1990) |
| "We have observed two cases of chlorpromazine-induced neuroleptic malignant syndrome (NMS); both were transiently responsive to intravenous diazepam challenge, but not to blind placebo or amyobarbitol." | 5.05 | Chlorpromazine-induced neuroleptic malignant syndrome and its response to diazepam. ( Lew, TY; Tollefson, G, 1983) |
| "Vigabatrin was specifically designed to enhance gamma-aminobutyric acid (GABA) function in the CNS." | 3.77 | Vigabatrin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in epilepsy and disorders of motor control. ( Grant, SM; Heel, RC, 1991) |
| " We present a case of asterixis as a cause of falls and near falls in a patient with metastatic breast cancer and normal mental status who was receiving gabapentin." | 3.73 | Asterixis related to gabapentin as a cause of falls. ( Babiy, M; Hand, M; Herklotz, M; Stubblefield, MD, 2005) |
| "We report two cases of unusual movement disorders associated with the use of gabapentin (GBP) in patients being treated for epilepsy who were otherwise neurologically intact." | 3.69 | Movement disorders associated with the use of gabapentin. ( Krahn, LE; Reeves, AL; Sharbrough, FW; So, EL, 1996) |
| " I report a patient who developed the syndrome during treatment for schizophrenia with the antipsychotic agent molindone hydrochloride." | 3.68 | Neuroleptic-induced "painful legs and moving toes" syndrome: successful treatment with clonazepam and baclofen. ( Sandyk, R, 1990) |
| "We measured the contents of gamma-aminobutyric acid (GABA) and of other amino compounds in five regions of autopsied brain from 18 patients with schizophrenia and from a large group of adult control subjects dying without any neurological or psychiatric disorder." | 3.67 | Schizophrenia, tardive dyskinesia, and brain GABA. ( Hansen, S; Jones, K; Perry, TL, 1989) |
| " Tolerance developed to the antidyskinetic effect of clonazepam in the five patients whose long-term use of the drug was followed, but a 2-week clonazepam-free period recaptured its antidyskinetic effect." | 2.67 | Clonazepam treatment of tardive dyskinesia: a practical GABAmimetic strategy. ( Jacobson, R; Kaup, BA; Nguyen, JA; Strauss, ME; Tamminga, CA; Thaker, GK, 1990) |
| "Levodopa is the most effective agent to alleviate motor dysfunction in Parkinson's disease but its long-term use is associated with the development of dyskinesias." | 2.44 | Levodopa-induced dyskinesias in Parkinson's disease: etiology, impact on quality of life, and treatments. ( Encarnacion, EV; Hauser, RA, 2008) |
| "Among psychiatric disorders the acute symptoms of schizophrenia are exacerbated by enhanced GABA-ergic function." | 2.36 | Pharmacology of GABA. ( Meldrum, B, 1982) |
| "The dichotomy of Parkinson's disease; akinesia with increased tone, and the mirror effects in Huntington's disease; hemiballismus and tardive dyskinesia, hyperkinesia with decreased tone are explained as due to two outputs of the system with an intervening inhibitory neuron which reverses the sign." | 2.36 | The basal ganglia in extrapyramidal dysfunction. ( Barnes, CD, 1983) |
| " Chronic administration of haloperidol (1 mg/kg, i." | 1.35 | Progesterone attenuates neuroleptic-induced orofacial dyskinesia via the activity of its metabolite, allopregnanolone, a positive GABA(A) modulating neurosteroid. ( Bishnoi, M; Chopra, K; Kulkarni, SK, 2008) |
| "Treatment with baclofen (4 mg/kg) did not modify spontaneous VCM." | 1.33 | Effects of baclofen on reserpine-induced vacuous chewing movements in mice. ( Abílio, VC; Castro, JP; Frussa-Filho, R; Fukushiro, DF; Medrano, WA; Ribeiro, Rde A; Silva, RH, 2006) |
| " On day 10, the locomotor response to L-dopa was significantly potentiated by chronic administration of idazoxan." | 1.31 | Noradrenoceptor antagonism with idazoxan improves L-dopa-induced dyskinesias in MPTP monkeys. ( Bédard, PJ; Doan, VD; Grondin, R; Hadj Tahar, A; Ladure, P, 2000) |
| "Treatment of Parkinson's disease with L-dopa is plagued in a majority of patients by dyskinesias." | 1.31 | Noradrenoceptor antagonism with idazoxan improves L-dopa-induced dyskinesias in MPTP monkeys. ( Bédard, PJ; Doan, VD; Grondin, R; Hadj Tahar, A; Ladure, P, 2000) |
| "Acute and chronic administration of vigabatrin, a selective inactivator of GABA-T, suppresses haloperidol-induced dyskinesias at low doses without preventing the enhancement of striatal dopamine D2 receptor density or the development of vacuous chewing movements." | 1.29 | Suppression of haloperidol-induced oral dyskinesias in rats by vigabatrin. ( Elands, J; Gobaille, S; Grauffel, C; Knödgen, B; Moran, P; Sarhan, S; Seiler, N; van den Buuse, M, 1995) |
| "Chronic administration of haloperidol to male Sprague Dawley rats for 6 months at a dosage of 1." | 1.29 | Tiagabine inhibits haloperidol-induced oral dyskinesias in rats. ( Friedman, MB; Gao, XM; Kakigi, T; Tamminga, CA, 1994) |
| " This phenomenon, probably due to the inhibition of the striato-nigral GABA-ergic pathway, could serve as an easy and reliable model for the human tardive dyskinesias dues to the chronic administration of neuroleptics." | 1.28 | [Oral dyskinesia in rats after a single administration of haloperidol combined with GABA-linoleamide. A model of dyskinesia in man]. ( Vamvakides, A, 1989) |
| "In ongoing studies of chronic administration of neuroleptics to monkeys (Cebus apella) and rats, the regional distribution of glutamic acid decarboxylase (GAD) and brain levels of homovanillic acid were examined." | 1.27 | Experimental tardive dyskinesia. ( Gunne, LM; Häggström, JE, 1985) |
| "Tetrahydroisoxazolopyridinol (THIP), a GABA receptor agonist, gamma-acetylenic-GABA(GAG) and gamma-vinyl-GABA(GVG), two GABA transaminase inhibitors were given in single parenteral doses to three Cebus apella monkeys with persistent dyskinetic movements induced by earlier long-term administration of haloperidol." | 1.27 | GABA agonists in cebus monkeys with neuroleptic-induced persistent dyskinesias. ( Andersson, U; Häggström, JE, 1988) |
| " While numerous reports of the partial effectiveness of acute treatment with cholinergic or GABAergic agents have appeared, the effects of chronic administration of these substance are unclear." | 1.26 | Symptomatic treatment of tardive dyskinesia: a word of caution. ( Kucharski, LT; Unterwald, EM, 1981) |
| "Muscimol, thought to be a agonist of gamma-aminobutyric acid (GABA), was administered to eight neuroleptic-free subjects with tardive dyskinesia." | 1.26 | Improvement in tardive dyskinesia after muscimol therapy. ( Chase, TN; Crayton, JW; Tamminga, CA, 1979) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 80 (56.34) | 18.7374 |
| 1990's | 15 (10.56) | 18.2507 |
| 2000's | 32 (22.54) | 29.6817 |
| 2010's | 10 (7.04) | 24.3611 |
| 2020's | 5 (3.52) | 2.80 |
| Authors | Studies |
|---|---|
| Nudelman, A | 1 |
| Gil-Ad, I | 1 |
| Shpaisman, N | 1 |
| Terasenko, I | 1 |
| Ron, H | 1 |
| Savitsky, K | 1 |
| Geffen, Y | 1 |
| Weizman, A | 1 |
| Rephaeli, A | 1 |
| Avila-Luna, A | 1 |
| Gálvez-Rosas, A | 1 |
| Aguirre-Pérez, A | 1 |
| Hidalgo-Bravo, A | 1 |
| Alfaro-Rodriguez, A | 1 |
| Ríos, C | 1 |
| Arias-Montaño, JA | 1 |
| Bueno-Nava, A | 1 |
| Abe, Y | 1 |
| Yagishita, S | 1 |
| Sano, H | 1 |
| Sugiura, Y | 1 |
| Dantsuji, M | 1 |
| Suzuki, T | 1 |
| Mochizuki, A | 1 |
| Yoshimaru, D | 1 |
| Hata, J | 1 |
| Matsumoto, M | 1 |
| Taira, S | 1 |
| Takeuchi, H | 1 |
| Okano, H | 1 |
| Ohno, N | 1 |
| Suematsu, M | 1 |
| Inoue, T | 1 |
| Nambu, A | 1 |
| Watanabe, M | 1 |
| Tanaka, KF | 1 |
| Kiessling, CY | 1 |
| Lanza, K | 1 |
| Feinberg, E | 1 |
| Bishop, C | 1 |
| Nishijima, H | 1 |
| Mori, F | 1 |
| Arai, A | 1 |
| Zhu, G | 1 |
| Wakabayashi, K | 1 |
| Okada, M | 1 |
| Ueno, S | 1 |
| Ichinohe, N | 1 |
| Suzuki, C | 1 |
| Kon, T | 1 |
| Tomiyama, M | 1 |
| Brugnoli, A | 2 |
| Pisanò, CA | 1 |
| Morari, M | 9 |
| Alabed, S | 1 |
| Latifeh, Y | 1 |
| Mohammad, HA | 1 |
| Bergman, H | 1 |
| Mabrouk, OS | 2 |
| Mela, F | 3 |
| Calcagno, M | 1 |
| Budri, M | 1 |
| Viaro, R | 1 |
| Dekundy, A | 2 |
| Parsons, CG | 1 |
| Auberson, YP | 1 |
| Paolone, G | 1 |
| Arcuri, L | 1 |
| Mercatelli, D | 1 |
| McCreary, AC | 1 |
| Varney, MA | 1 |
| Newman-Tancredi, A | 1 |
| Solís, O | 1 |
| García-Sanz, P | 1 |
| Herranz, AS | 1 |
| Asensio, MJ | 1 |
| Moratalla, R | 1 |
| Varty, GB | 1 |
| Hodgson, RA | 1 |
| Pond, AJ | 1 |
| Grzelak, ME | 1 |
| Parker, EM | 1 |
| Hunter, JC | 1 |
| Marti, M | 6 |
| Trapella, C | 1 |
| Rangel-Barajas, C | 1 |
| Silva, I | 1 |
| Lopéz-Santiago, LM | 1 |
| Aceves, J | 1 |
| Erlij, D | 1 |
| Florán, B | 1 |
| Bido, S | 2 |
| Cenci, MA | 2 |
| Rodi, D | 1 |
| Li, Q | 1 |
| Guerrini, R | 1 |
| Fasano, S | 1 |
| Morella, I | 1 |
| Tozzi, A | 1 |
| Brambilla, R | 1 |
| Calabresi, P | 1 |
| Simonato, M | 1 |
| Bezard, E | 1 |
| Fox, SH | 3 |
| Henry, B | 1 |
| Hill, M | 3 |
| Crossman, A | 1 |
| Brotchie, J | 1 |
| Hardoy, MC | 2 |
| Carta, MG | 2 |
| Carpiniello, B | 1 |
| Cianchetti, C | 1 |
| Congia, S | 1 |
| D'Errico, I | 1 |
| Emanuelli, G | 1 |
| Garonna, F | 1 |
| Hardoy, MJ | 2 |
| Nardini, M | 1 |
| Kase, H | 1 |
| Aoyama, S | 1 |
| Ichimura, M | 1 |
| Ikeda, K | 1 |
| Ishii, A | 1 |
| Kanda, T | 1 |
| Koga, K | 1 |
| Koike, N | 1 |
| Kurokawa, M | 1 |
| Kuwana, Y | 1 |
| Mori, A | 1 |
| Nakamura, J | 1 |
| Nonaka, H | 1 |
| Ochi, M | 1 |
| Saki, M | 1 |
| Shimada, J | 1 |
| Shindou, T | 1 |
| Shiozaki, S | 1 |
| Suzuki, F | 1 |
| Takeda, M | 1 |
| Yanagawa, K | 1 |
| Richardson, PJ | 1 |
| Jenner, P | 1 |
| Bedard, P | 1 |
| Borrelli, E | 1 |
| Hauser, RA | 2 |
| Chase, TN | 4 |
| Sechi, G | 1 |
| Murgia, B | 1 |
| Sau, G | 1 |
| Peddone, L | 1 |
| Tirotto, A | 1 |
| Barrocu, M | 1 |
| Rosati, G | 1 |
| Ishiwari, K | 1 |
| Mingote, S | 1 |
| Correa, M | 1 |
| Trevitt, JT | 1 |
| Carlson, BB | 1 |
| Salamone, JD | 1 |
| Babiy, M | 1 |
| Stubblefield, MD | 1 |
| Herklotz, M | 1 |
| Hand, M | 1 |
| van der Stelt, M | 1 |
| Crossman, AR | 2 |
| Petrosino, S | 1 |
| Di Marzo, V | 1 |
| Brotchie, JM | 2 |
| Horvath, J | 1 |
| Coeytaux, A | 1 |
| Jallon, P | 1 |
| Landis, T | 1 |
| Temperli, P | 1 |
| Burkhard, PR | 1 |
| Heckmann, JG | 1 |
| Ulrich, K | 1 |
| Dütsch, M | 1 |
| Neundörfer, B | 1 |
| Castro, JP | 1 |
| Frussa-Filho, R | 1 |
| Fukushiro, DF | 1 |
| Silva, RH | 1 |
| Medrano, WA | 1 |
| Ribeiro, Rde A | 1 |
| Abílio, VC | 1 |
| Deogaonkar, A | 1 |
| Deogaonkar, M | 1 |
| Lee, JY | 1 |
| Ebrahim, Z | 1 |
| Schubert, A | 1 |
| Raju, PM | 1 |
| Walker, RW | 1 |
| Lee, MA | 1 |
| Danysz, W | 1 |
| Bishnoi, M | 1 |
| Chopra, K | 1 |
| Kulkarni, SK | 4 |
| Carta, AR | 1 |
| Frau, L | 1 |
| Lucia, F | 1 |
| Pinna, A | 1 |
| Annalisa, P | 1 |
| Pontis, S | 1 |
| Silvia, P | 1 |
| Simola, N | 1 |
| Nicola, S | 1 |
| Schintu, N | 1 |
| Nicoletta, S | 1 |
| Morelli, M | 1 |
| Micaela, M | 1 |
| Encarnacion, EV | 1 |
| Berger, PA | 3 |
| Rexroth, K | 1 |
| Barbaccia, ML | 1 |
| Trabucchi, M | 1 |
| Casey, DE | 4 |
| Gerlach, J | 5 |
| Magelund, G | 2 |
| Christensen, TR | 2 |
| Logothetis, J | 1 |
| Paraschos, A | 1 |
| Frangos, E | 1 |
| Hollister, LE | 1 |
| Lloyd, KG | 3 |
| Worms, P | 1 |
| Wray, SR | 1 |
| Melville, GN | 1 |
| Grell, GA | 1 |
| Edge, PC | 1 |
| Gale, K | 2 |
| Casu, M | 1 |
| Ananth, J | 1 |
| Alphs, L | 1 |
| Davis, JM | 1 |
| Tanner, CM | 1 |
| Tamminga, CA | 12 |
| Thaker, GK | 8 |
| Ferraro, TN | 2 |
| Hare, TA | 3 |
| Meldrum, B | 1 |
| Barnes, CD | 1 |
| Hammond, EJ | 3 |
| Wilder, BJ | 3 |
| Bruni, J | 1 |
| Bartholini, G | 2 |
| Neale, R | 1 |
| Gerhardt, S | 1 |
| Liebman, JM | 1 |
| Wesemann, W | 1 |
| Sontag, KH | 1 |
| Maj, J | 1 |
| Bjørndal, N | 1 |
| Christensson, E | 1 |
| Robin, MM | 2 |
| Palfreyman, MG | 2 |
| Zraika, MM | 1 |
| Schechter, PJ | 2 |
| Marsden, CD | 1 |
| Sheehy, MP | 1 |
| Rastogi, SK | 2 |
| Rastogi, RB | 2 |
| Singhal, RL | 2 |
| Lapierre, YD | 2 |
| Lew, TY | 1 |
| Tollefson, G | 1 |
| Kucharski, LT | 1 |
| Unterwald, EM | 1 |
| Cutler, NR | 1 |
| Post, RM | 1 |
| Robin, M | 1 |
| Palfreyman, M | 1 |
| Zraika, M | 1 |
| Schechter, P | 1 |
| Crews, EL | 1 |
| Seiler, N | 1 |
| Grauffel, C | 1 |
| Elands, J | 1 |
| van den Buuse, M | 1 |
| Knödgen, B | 1 |
| Sarhan, S | 1 |
| Moran, P | 1 |
| Gobaille, S | 1 |
| Gao, XM | 1 |
| Kakigi, T | 1 |
| Friedman, MB | 1 |
| Gunne, LM | 7 |
| Andrén, PE | 2 |
| Shirakawa, O | 2 |
| Maeda, K | 1 |
| Sakai, K | 1 |
| Spooren, WP | 1 |
| Mulders, WH | 1 |
| Veening, JG | 1 |
| Cools, AR | 2 |
| Buetefisch, CM | 1 |
| Gutierrez, A | 1 |
| Gutmann, L | 1 |
| Reeves, AL | 1 |
| So, EL | 1 |
| Sharbrough, FW | 1 |
| Krahn, LE | 1 |
| Cabras, PL | 1 |
| Grondin, R | 1 |
| Hadj Tahar, A | 1 |
| Doan, VD | 1 |
| Ladure, P | 1 |
| Bédard, PJ | 1 |
| Sachdev, PS | 1 |
| Grimm, JW | 1 |
| See, RE | 2 |
| Tanii, H | 1 |
| Zang, X | 1 |
| Saito, N | 1 |
| Saijoh, K | 1 |
| Naidu, PS | 3 |
| Raghavendra, V | 1 |
| Ghaemi, SN | 1 |
| Ko, JY | 1 |
| Berglind, WJ | 1 |
| Sieradzan, KA | 1 |
| Dick, JP | 1 |
| Norton, JW | 1 |
| Quarles, E | 1 |
| Lastres-Becker, I | 1 |
| Hansen, HH | 1 |
| Berrendero, F | 1 |
| De Miguel, R | 1 |
| Pérez-Rosado, A | 1 |
| Manzanares, J | 1 |
| Ramos, JA | 1 |
| Fernández-Ruiz, J | 1 |
| Chien, C | 1 |
| Jung, K | 1 |
| Ross-Townsend, A | 1 |
| Crayton, JW | 1 |
| Costentin, J | 1 |
| Mackay, AV | 1 |
| Sheppard, GP | 1 |
| Faull, KF | 1 |
| DoAmaral, JR | 1 |
| Barchas, JD | 1 |
| Makeeva, VL | 1 |
| Scarnati, E | 1 |
| Forchetti, C | 1 |
| Ruggieri, S | 1 |
| Agnoli, A | 1 |
| Standefer, MJ | 1 |
| Dill, RE | 1 |
| Cassady, SL | 1 |
| Moran, M | 1 |
| Birt, A | 1 |
| Kaneda, H | 1 |
| Dale, J | 1 |
| Goodman, L | 1 |
| Bachus, SE | 2 |
| Grant, SM | 1 |
| Heel, RC | 1 |
| Nguyen, JA | 3 |
| Strauss, ME | 1 |
| Jacobson, R | 1 |
| Kaup, BA | 1 |
| Sandyk, R | 2 |
| Ciu, Z | 1 |
| Gao, BL | 1 |
| Häggström, JE | 4 |
| Johansson, P | 1 |
| Levin, ED | 1 |
| Terenius, L | 1 |
| Spooren, W | 1 |
| Bezemer, R | 1 |
| Cuypers, E | 1 |
| Jaspers, R | 1 |
| Groenewegen, H | 1 |
| Perry, TL | 1 |
| Hansen, S | 1 |
| Jones, K | 1 |
| Vamvakides, A | 4 |
| Ungerstedt, U | 1 |
| Herrera-Marschitz, M | 1 |
| Forster, C | 1 |
| Arushanian, EB | 1 |
| Cross, AJ | 1 |
| Crow, TJ | 1 |
| Ferrier, IN | 1 |
| Johnson, JA | 1 |
| Johnstone, EC | 1 |
| Owen, F | 1 |
| Owens, DG | 1 |
| Poulter, M | 1 |
| Morselli, PL | 2 |
| Fournier, V | 2 |
| Bossi, L | 1 |
| Musch, B | 1 |
| Kashihara, K | 1 |
| Ebara, T | 1 |
| Yamamoto, M | 1 |
| Ogawa, T | 1 |
| Harada, T | 1 |
| Otsuki, S | 1 |
| Perrault, G | 1 |
| Zivkovic, B | 1 |
| Rondot, P | 3 |
| Bathien, N | 2 |
| Mithani, S | 1 |
| Atmadja, S | 1 |
| Baimbridge, KG | 1 |
| Fibiger, HC | 1 |
| Andersson, U | 1 |
| Ziegler, M | 1 |
| Scheel-Krüger, J | 1 |
| Arnt, J | 1 |
| Alphs, LD | 1 |
| Lafferman, J | 1 |
| Jeste, DV | 1 |
| Lohr, JB | 1 |
| Clark, K | 1 |
| Wyatt, RJ | 1 |
| Toth, E | 1 |
| Lajtha, A | 1 |
| Gaio, JM | 1 |
| Pollak, P | 1 |
| Hommel, M | 1 |
| Perret, J | 1 |
| Stahl, SM | 1 |
| Thornton, JE | 1 |
| Simpson, ML | 1 |
| Napoliello, MJ | 1 |
| Mukherjee, S | 1 |
| Wisniewski, A | 1 |
| Bilder, R | 1 |
| Sackeim, HA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II, Randomized, Open-label, Double-blind, Two-center Study to Evaluate the Tolerability, Safety and Dose-finding of Oil Cannabis Preparation for Pain in Parkinson's Disease[NCT03639064] | Phase 2 | 15 participants (Anticipated) | Interventional | 2020-12-01 | Recruiting | ||
| Open-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia (LID)[NCT02202551] | Phase 3 | 223 participants (Actual) | Interventional | 2014-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"To evaluate clinical progression of PD as assessed by the MDS-UPDRS, combined score, Parts I, II, and III.~Part I - non-motor experiences of daily living; Part II - motor experiences of daily living; Part III - motor examination. Parts I and II each contain 13 questions measured on a 5-point scale (0-4). Part III contains 18 objective rater assessments of the motor signs of PD measured on a 5-point scale (0-4).~Total range for combined score (Part I-III) is = 0-176. Generally for MDS-UPDRS scores and sub-scores, the lower the score, the better.~Parts I, II, and III are summed to make the total score." (NCT02202551)
Timeframe: Up to 101 weeks. MDS-UPDRS was performed at the following visits: Screening, Week 8, Week 16, Week 28, Week 40, Week 52, Week 64, Week 76, Week 88, Week 100 (or ET).
| Intervention | units on a scale (Mean) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Baseline | Change from Baseline at Week 8 | Change from Baseline at Week 16 | Change from Baseline at Week 28 | Change from Baseline at Week 40 | Change from Baseline at Week 52 | Change from Baseline at Week 64 | Change from Baseline at Week 76 | Change from Baseline at Week 88 | Change from Baseline at Week 100 | |
| ADS-5102 1A | 41.8 | 1.2 | 1.6 | 4.8 | 7.5 | 13.2 | 8.8 | 11.7 | 11.3 | 11.4 |
| ADS-5102 Group 1P | 45.6 | -2.8 | -1.4 | 1.5 | -0.4 | 2.6 | 2.6 | 7.3 | 3.7 | 3.7 |
| ADS-5102 Group 2 | 52.8 | 0.8 | 5.7 | 6.5 | 1.6 | 6.1 | 6.1 | 9.4 | 6.4 | 6.5 |
| ADS-5102 Group 3 | 52.4 | -5.3 | -5.2 | -5.3 | -4.8 | -4.6 | -4.6 | -4.9 | 0.9 | 4.1 |
"This component (Questions 4.1 - 4.6) includes time spent with dyskinesia, functional impact of dyskinesia, time spent in OFF state, functional impact of fluctuations, complexity of motor fluctuations, painful OFF-state dystonia. Questions 4.1-4.6 are summed to make the Part IV score.~Generally for MDS-UPDRS scores and sub-scores, the lower the score, the better. Total range for Part IV is = 0-24" (NCT02202551)
Timeframe: 100 Weeks. MDS-UPDRS was performed at the following visits: Screening, Week 8, Week 16, Week 28, Week 40, Week 52, Week 64, Week 76, Week 88, Week 100 (or ET).
| Intervention | units on a scale (Mean) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Baseline | Change in Baseline from Week 8 | Change in Baseline from Week 16 | Change from Baseline at Week 28 | Change from Baseline at Week 40 | Change from Baseline at Week 52 | Change from Baseline at Week 64 | Change from Baseline at Week 76 | Change from Baseline at Week 88 | Change from Baseline at Week 100 | |
| Group 1a | 6.5 | -0.2 | -0.8 | -0.3 | 0.0 | 0.2 | 0.4 | 0.9 | 0.4 | 0.4 |
| Group 1P | 9.6 | -3.4 | -3.2 | -3.3 | -2.8 | -2.9 | -3.3 | -2.9 | -2.8 | -2.4 |
| Group 2 | 9.8 | -3.6 | -1.1 | -1.4 | -2.9 | -2.5 | -1.9 | -2.7 | -3.7 | -3.6 |
| Group 3 | 10.4 | -4.0 | -3.9 | -4.4 | -4.7 | -3.6 | -2.5 | -3.7 | -4.3 | -3.6 |
The primary objective of the study was to evaluate the safety and tolerability of ADS-5102 oral capsules, an extended release (ER) formulation of amantadine, administered at a dose of 340 mg once daily at bedtime for the treatment of levodopa-induced dyskinesia (LID) in subjects with Parkinson's disease (PD). (NCT02202551)
Timeframe: Up to 101 weeks
| Intervention | Participants (Count of Participants) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| AE | Study drug-related AE | SAEs | Permanent discontinuation due to AE | Permanent discontinuation due to drug-related AE | Mild AEs | Moderate AEs | Mild drug-related AE | Moderate drug-related AE | Severe drug-related AE | |
| Group 1a | 57 | 31 | 16 | 12 | 4 | 12 | 25 | 16 | 12 | 3 |
| Group 1P | 70 | 45 | 21 | 21 | 15 | 13 | 36 | 15 | 23 | 7 |
| Group 2 | 23 | 16 | 6 | 6 | 4 | 3 | 13 | 3 | 12 | 1 |
| Group 3 | 55 | 32 | 17 | 10 | 8 | 11 | 26 | 5 | 22 | 5 |
30 reviews available for gamma-aminobutyric acid and Dyskinesia, Drug-Induced
| Article | Year |
|---|---|
Gamma-aminobutyric acid agonists for antipsychotic-induced tardive dyskinesia.
Topics: Antipsychotic Agents; Baclofen; Dyskinesia, Drug-Induced; GABA Agonists; gamma-Aminobutyric Acid; Hu | 2018 |
Progress in pursuit of therapeutic A2A antagonists: the adenosine A2A receptor selective antagonist KW6002: research and development toward a novel nondopaminergic therapy for Parkinson's disease.
Topics: Adenosine A2 Receptor Antagonists; Animals; Antiparkinson Agents; Clinical Trials as Topic; Corpus S | 2003 |
Levodopa-induced dyskinesias in Parkinson's disease: etiology, impact on quality of life, and treatments.
Topics: Aged; Animals; Antiparkinson Agents; Basal Ganglia; Corpus Striatum; Deep Brain Stimulation; Dopamin | 2008 |
Tardive dyskinesia: a biological appraoch.
Topics: Animals; Antipsychotic Agents; Dyskinesia, Drug-Induced; gamma-Aminobutyric Acid; Haloperidol; Human | 1980 |
Neuropharmacological actions of GABA agonists: predictability for their clinical usefulness.
Topics: Antipsychotic Agents; Brain Chemistry; Dyskinesia, Drug-Induced; Epilepsy; gamma-Aminobutyric Acid; | 1981 |
Current concepts of abnormal motor disorder: an experimental model of attentional deficit disorder.
Topics: Amphetamine; Animals; Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Avoidance | 1981 |
Dynamic utilization of GABA in substantia nigra: regulation by dopamine and GABA in the striatum, and its clinical and behavioral implications.
Topics: 4-Aminobutyrate Transaminase; Afferent Pathways; Aminocaproates; Animals; Basal Ganglia; Behavior, A | 1981 |
Current psychopathological theories of tardive dyskinesia and their implications for future research.
Topics: Acetylcholine; Adult; Aged; Animals; Antipsychotic Agents; Brain; Dopamine; Dyskinesia, Drug-Induced | 1982 |
Treatment of tardive dyskinesia: other therapies.
Topics: Dopamine; Dyskinesia, Drug-Induced; gamma-Aminobutyric Acid; Humans; Neurotransmitter Agents; Norepi | 1983 |
Pharmacology of GABA.
Topics: 4-Aminobutyrate Transaminase; Anxiety Disorders; Autonomic Nervous System; Barbiturates; Benzodiazep | 1982 |
The basal ganglia in extrapyramidal dysfunction.
Topics: Basal Ganglia; Basal Ganglia Diseases; Corpus Striatum; Dyskinesia, Drug-Induced; Feedback; gamma-Am | 1983 |
Central actions of valproic acid in man and in experimental models of epilepsy.
Topics: 4-Aminobutyrate Transaminase; Action Potentials; Alcohol Oxidoreductases; Aldehyde Oxidoreductases; | 1981 |
GABA system, GABA receptor agonists and dyskinesia.
Topics: Basal Ganglia; Cholinergic Fibers; Dopamine; Dyskinesia, Drug-Induced; gamma-Aminobutyric Acid; Huma | 1983 |
[Pharmacodynamics and pharmacokinetics of memantine].
Topics: Amantadine; Animals; Antidepressive Agents; Body Temperature; Catalepsy; Dopamine; Dyskinesia, Drug- | 1983 |
GABA system: clinical research and treatment of tardive dyskinesia.
Topics: Alkynes; Aminocaproates; Benzodiazepines; Clinical Trials as Topic; Corpus Striatum; Dopamine; Dyski | 1983 |
Tardive dyskinesia: pathophysiology and animal models.
Topics: Age Factors; Animals; Antipsychotic Agents; Basal Ganglia; Behavior, Animal; Disease Models, Animal; | 2000 |
The current status of tardive dyskinesia.
Topics: Age Factors; Antipsychotic Agents; Cholinergic Antagonists; Dyskinesia, Drug-Induced; Free Radicals; | 2000 |
Neurotransmitter interactions related to central dopamine neurons.
Topics: Acetylcholine; Animals; Antipsychotic Agents; Behavior, Animal; Brain; Central Nervous System; Dopam | 1978 |
[Modulation of dopaminergic receptor sensitivity in the central nervous system: important parameters in synaptic function regulation].
Topics: Acetylcholine; Adenylyl Cyclases; Animals; Antipsychotic Agents; Apomorphine; Behavior; Corpus Stria | 1979 |
Vigabatrin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in epilepsy and disorders of motor control.
Topics: 4-Aminobutyrate Transaminase; Adult; Aged; Aminocaproates; Animals; Ataxia; Child; Dyskinesia, Drug- | 1991 |
[Significance of GABA-energic system in the central nervous system in clinical psychologic medicine].
Topics: Animals; Brain Chemistry; Dyskinesia, Drug-Induced; gamma-Aminobutyric Acid; Hepatic Encephalopathy; | 1990 |
Neurobiochemical changes in tardive dyskinesia.
Topics: Animals; Antipsychotic Agents; Apomorphine; Cebus; Dyskinesia, Drug-Induced; gamma-Aminobutyric Acid | 1988 |
GABAmimetic treatments for tardive dyskinesia: efficacy and mechanism.
Topics: Animals; Brain Chemistry; Dyskinesia, Drug-Induced; gamma-Aminobutyric Acid; Humans | 1989 |
[Neuroleptic parkinsonism and tardive dyskinesia and methods of pharmacologically correcting these pathologic conditions (review)].
Topics: Animals; Antipsychotic Agents; Cats; Cholinergic Fibers; Corpus Striatum; Dopamine; Dyskinesia, Drug | 1985 |
[Implications of GABAergic synapses in neuropsychiatry].
Topics: 4-Aminobutyrate Transaminase; Animals; Anti-Anxiety Agents; Anticonvulsants; Antidepressive Agents; | 1985 |
[Tardive dyskinesias. Epidemiology and physiopathology].
Topics: Adult; Aged; Antipsychotic Agents; Denmark; Dyskinesia, Drug-Induced; Female; gamma-Aminobutyric Aci | 1987 |
Gamma-vinyl GABA.
Topics: 4-Aminobutyrate Transaminase; Amino Acids; Aminocaproates; Animals; Behavior, Animal; beta-Alanine; | 1985 |
Pharmacological treatments of tardive dyskinesia in the 1980s.
Topics: Dyskinesia, Drug-Induced; gamma-Aminobutyric Acid; Humans; Norepinephrine; Parasympatholytics; Paras | 1988 |
[Effect of glycine-steatamide or glutamic acid palmitamide on oral dyskinesia, obtained by a single administration of haloperidol combined with GABA-linoleamide in rats].
Topics: Animals; Drug Combinations; Dyskinesia, Drug-Induced; Female; gamma-Aminobutyric Acid; Glutamates; G | 1988 |
Gamma-vinyl GABA: a new antiepileptic drug.
Topics: 4-Aminobutyrate Transaminase; Amino Acids; Aminocaproates; Animals; Anticonvulsants; Brain Chemistry | 1985 |
17 trials available for gamma-aminobutyric acid and Dyskinesia, Drug-Induced
| Article | Year |
|---|---|
Gabapentin in antipsychotic-induced tardive dyskinesia: results of 1-year follow-up.
Topics: Acetates; Adult; Amines; Anticonvulsants; Antipsychotic Agents; Cyclohexanecarboxylic Acids; Dyskine | 2003 |
gamma-Acetylenic GABA in tardive dyskinesia.
Topics: 4-Aminobutyrate Transaminase; Adult; Aged; Alkynes; Aminocaproates; Antipsychotic Agents; Brain; Dop | 1980 |
GABA agonist treatment improves tardive dyskinesia.
Topics: 4-Aminobutyrate Transaminase; Aminocaproates; Clinical Trials as Topic; Double-Blind Method; Dyskine | 1983 |
GABA system: clinical research and treatment of tardive dyskinesia.
Topics: Alkynes; Aminocaproates; Benzodiazepines; Clinical Trials as Topic; Corpus Striatum; Dopamine; Dyski | 1983 |
GABA and movement disorders.
Topics: Anticonvulsants; Baclofen; Clinical Trials as Topic; Double-Blind Method; Dyskinesia, Drug-Induced; | 1981 |
Chlorpromazine-induced neuroleptic malignant syndrome and its response to diazepam.
Topics: Brain; Chlorpromazine; Diazepam; Dopamine; Dyskinesia, Drug-Induced; Dystonia; Female; Fever; gamma- | 1983 |
Cannabinoids reduce levodopa-induced dyskinesia in Parkinson's disease: a pilot study.
Topics: Aged; Animals; Cross-Over Studies; Culture Techniques; Double-Blind Method; Dronabinol; Dyskinesia, | 2001 |
Efficacies of agents related to GABA, dopamine, and acetylcholine in the treatment of tardive dyskinesia [proceedings].
Topics: Acetylcholine; Clinical Trials as Topic; Deanol; Dopamine; Dyskinesia, Drug-Induced; Ethanolamines; | 1978 |
Pharmacotherapeutic trials in tardive dyskinesia.
Topics: Acetylcholine; Antipsychotic Agents; Clinical Trials as Topic; Double-Blind Method; Drug Administrat | 1979 |
GABA agonist-induced changes in motor, oculomotor, and attention measures correlate in schizophrenics with tardive dyskinesia.
Topics: Adult; Antipsychotic Agents; Attention; Chronic Disease; Double-Blind Method; Dyskinesia, Drug-Induc | 1992 |
Vigabatrin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in epilepsy and disorders of motor control.
Topics: 4-Aminobutyrate Transaminase; Adult; Aged; Aminocaproates; Animals; Ataxia; Child; Dyskinesia, Drug- | 1991 |
Clonazepam treatment of tardive dyskinesia: a practical GABAmimetic strategy.
Topics: Adult; Antipsychotic Agents; Athetosis; Chorea; Clonazepam; Double-Blind Method; Dyskinesia, Drug-In | 1990 |
Clinical activity of GABA agonists in neuroleptic- and L-dopa-induced dyskinesia.
Topics: Antipsychotic Agents; Clinical Trials as Topic; Dose-Response Relationship, Drug; Double-Blind Metho | 1985 |
Movement disorders in patients with coexistent neuroleptic-induced tremor and tardive dyskinesia: EMG and pharmacological study.
Topics: Antipsychotic Agents; Clinical Trials as Topic; Corpus Striatum; Double-Blind Method; Dyskinesia, Dr | 1987 |
Therapeutic response to progabide in neuroleptic- and L-dopa-induced dyskinesias.
Topics: Adult; Aged; Antipsychotic Agents; Clinical Trials as Topic; Double-Blind Method; Dyskinesia, Drug-I | 1987 |
Brain gamma-aminobutyric acid abnormality in tardive dyskinesia. Reduction in cerebrospinal fluid GABA levels and therapeutic response to GABA agonist treatment.
Topics: Adult; Aminocaproates; Brain; Clinical Trials as Topic; Double-Blind Method; Dyskinesia, Drug-Induce | 1987 |
Gamma-vinyl GABA: a new antiepileptic drug.
Topics: 4-Aminobutyrate Transaminase; Amino Acids; Aminocaproates; Animals; Anticonvulsants; Brain Chemistry | 1985 |
98 other studies available for gamma-aminobutyric acid and Dyskinesia, Drug-Induced
| Article | Year |
|---|---|
A mutual prodrug ester of GABA and perphenazine exhibits antischizophrenic efficacy with diminished extrapyramidal effects.
Topics: Administration, Oral; Animals; Antipsychotic Agents; Biological Availability; Catalepsy; Dextroamphe | 2008 |
Chronic H
Topics: Animals; Cerebral Cortex; Corpus Striatum; Dopamine; Dyskinesia, Drug-Induced; gamma-Aminobutyric Ac | 2023 |
Shared GABA transmission pathology in dopamine agonist- and antagonist-induced dyskinesia.
Topics: Animals; Antiparkinson Agents; Dopamine; Dopamine Agonists; Dyskinesia, Drug-Induced; gamma-Aminobut | 2023 |
Dopamine receptor cooperativity synergistically drives dyskinesia, motor behavior, and striatal GABA neurotransmission in hemiparkinsonian rats.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Corpus Striatum; Dopamine Agoni | 2020 |
GABA storage and release in the medial globus pallidus in L-DOPA-induced dyskinesia priming.
Topics: Animals; Antiparkinson Agents; Dyskinesia, Drug-Induced; gamma-Aminobutyric Acid; Globus Pallidus; L | 2020 |
Striatal and nigral muscarinic type 1 and type 4 receptors modulate levodopa-induced dyskinesia and striato-nigral pathway activation in 6-hydroxydopamine hemilesioned rats.
Topics: Allosteric Regulation; Animals; Dopamine Agents; Dyskinesia, Drug-Induced; gamma-Aminobutyric Acid; | 2020 |
GluN2A and GluN2B NMDA receptor subunits differentially modulate striatal output pathways and contribute to levodopa-induced abnormal involuntary movements in dyskinetic rats.
Topics: Animals; Corpus Striatum; Dopamine; Dopamine Agents; Dyskinesia, Drug-Induced; gamma-Aminobutyric Ac | 2013 |
Eltoprazine prevents levodopa-induced dyskinesias by reducing striatal glutamate and direct pathway activity.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Dopamine; | 2015 |
The novel 5-HT1A receptor agonist, NLX-112 reduces l-DOPA-induced abnormal involuntary movements in rat: A chronic administration study with microdialysis measurements.
Topics: Animals; Anti-Dyskinesia Agents; Corpus Striatum; Cross-Over Studies; Dopamine; Dose-Response Relati | 2016 |
L-DOPA Reverses the Increased Free Amino Acids Tissue Levels Induced by Dopamine Depletion and Rises GABA and Tyrosine in the Striatum.
Topics: Amino Acids; Animals; Aspartic Acid; Corpus Striatum; Dopamine; Dyskinesia, Drug-Induced; Forelimb; | 2016 |
The effects of adenosine A2A receptor antagonists on haloperidol-induced movement disorders in primates.
Topics: Adenosine A2 Receptor Antagonists; Animals; Antipsychotic Agents; Caffeine; Catalepsy; Cebus; Corpus | 2008 |
The novel nociceptin/orphanin FQ receptor antagonist Trap-101 alleviates experimental parkinsonism through inhibition of the nigro-thalamic pathway: positive interaction with L-DOPA.
Topics: Animals; Antiparkinson Agents; Benzimidazoles; Disease Models, Animal; Dose-Response Relationship, D | 2008 |
Endogenous nociceptin/orphanin FQ (N/OFQ) contributes to haloperidol-induced changes of nigral amino acid transmission and parkinsonism: a combined microdialysis and behavioral study in naïve and nociceptin/orphanin FQ receptor knockout mice.
Topics: Animals; Antipsychotic Agents; Benzimidazoles; Disease Models, Animal; Dose-Response Relationship, D | 2010 |
L-DOPA-induced dyskinesia in hemiparkinsonian rats is associated with up-regulation of adenylyl cyclase type V/VI and increased GABA release in the substantia nigra reticulata.
Topics: Adenylyl Cyclases; Animals; Dyskinesia, Drug-Induced; Enzyme Inhibitors; gamma-Aminobutyric Acid; Le | 2011 |
Amantadine attenuates levodopa-induced dyskinesia in mice and rats preventing the accompanying rise in nigral GABA levels.
Topics: Amantadine; Animals; Antiparkinson Agents; Behavior, Animal; Data Interpretation, Statistical; Dyski | 2011 |
In vivo evidence for a differential contribution of striatal and nigral D1 and D2 receptors to L-DOPA induced dyskinesia and the accompanying surge of nigral amino acid levels.
Topics: Animals; Benzazepines; Corpus Striatum; Dopamine Antagonists; Dyskinesia, Drug-Induced; gamma-Aminob | 2012 |
Nociceptin/orphanin FQ receptor agonists attenuate L-DOPA-induced dyskinesias.
Topics: Animals; Anti-Dyskinesia Agents; Antiparkinson Agents; Autoradiography; Behavior, Animal; Dyskinesia | 2012 |
Stimulation of cannabinoid receptors reduces levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Benserazide; Callithrix | 2002 |
Asterixis and toxic encephalopathy induced by gabapentin.
Topics: Acetates; Aged; Amines; Anticonvulsants; Brain; Brain Diseases; Carbamazepine; Cyclohexanecarboxylic | 2004 |
The GABA uptake inhibitor beta-alanine reduces pilocarpine-induced tremor and increases extracellular GABA in substantia nigra pars reticulata as measured by microdialysis.
Topics: Animals; beta-Alanine; Chromatography, High Pressure Liquid; Disease Models, Animal; Dose-Response R | 2004 |
Asterixis related to gabapentin as a cause of falls.
Topics: Accidental Falls; Aged; Amines; Analgesics; Breast Neoplasms; Cyclohexanecarboxylic Acids; Diagnosis | 2005 |
A role for endocannabinoids in the generation of parkinsonism and levodopa-induced dyskinesia in MPTP-lesioned non-human primate models of Parkinson's disease.
Topics: Animals; Arachidonic Acids; Callithrix; Cannabinoid Receptor Modulators; Dyskinesia, Drug-Induced; E | 2005 |
Carbamazepine encephalopathy masquerading as Creutzfeldt-Jakob disease.
Topics: Aged; Amines; Analgesics, Non-Narcotic; Atrophy; Basal Ganglia; Brain; Brain Damage, Chronic; Carbam | 2005 |
Pregabalin associated asterixis.
Topics: Accidental Falls; Aged; Aged, 80 and over; Analgesics; Dyskinesia, Drug-Induced; Female; gamma-Amino | 2005 |
Effects of baclofen on reserpine-induced vacuous chewing movements in mice.
Topics: Adrenergic Uptake Inhibitors; Animals; Baclofen; Brain; Brain Chemistry; Dose-Response Relationship, | 2006 |
Propofol-induced dyskinesias controlled with dexmedetomidine during deep brain stimulation surgery.
Topics: Deep Brain Stimulation; Dexmedetomidine; Dyskinesia, Drug-Induced; gamma-Aminobutyric Acid; Humans; | 2006 |
Dyskinesia induced by gabapentin in idiopathic Parkinson's disease.
Topics: Aged; Amines; Antiparkinson Agents; Cyclohexanecarboxylic Acids; Dyskinesia, Drug-Induced; Gabapenti | 2007 |
Antagonism of metabotropic glutamate receptor type 5 attenuates l-DOPA-induced dyskinesia and its molecular and neurochemical correlates in a rat model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Brain; Disease Models, Animal; Drug Interactions; Dyskinesia, Drug-In | 2007 |
Progesterone attenuates neuroleptic-induced orofacial dyskinesia via the activity of its metabolite, allopregnanolone, a positive GABA(A) modulating neurosteroid.
Topics: Animals; Antipsychotic Agents; Brain Diseases; Control Groups; Disease Models, Animal; Dopamine; Dys | 2008 |
Behavioral and biochemical correlates of the dyskinetic potential of dopaminergic agonists in the 6-OHDA lesioned rat.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Antiparkinson Agents; Corpus St | 2008 |
Tardive dyskinesia: clinical, biological, and pharmacological perspectives.
Topics: Acetylcholine; Animals; Antipsychotic Agents; Choline; Corpus Striatum; Diagnosis, Differential; Dop | 1980 |
Side effects in preventive maintenance therapy with neuroleptics with special emphasis on tardive dyskinesia.
Topics: Antipsychotic Agents; Chronic Disease; Dyskinesia, Drug-Induced; gamma-Aminobutyric Acid; Humans; Pa | 1981 |
Treatment of tardive dyskinesia.
Topics: Antipsychotic Agents; Dopamine; Dyskinesia, Drug-Induced; gamma-Aminobutyric Acid; Humans | 1980 |
Noncatecholaminergic treatments of tardive dyskinesia.
Topics: Amantadine; Anti-Anxiety Agents; Benzodiazepines; Cyproheptadine; D-Ala(2),MePhe(4),Met(0)-ol-enkeph | 1982 |
Effects of dopamine agonists, catecholamine depletors, and cholinergic and GABAergic drugs on acute dyskinesias in squirrel monkeys.
Topics: Acute Disease; alpha-Methyltyrosine; Animals; Avoidance Learning; Catecholamines; Dyskinesia, Drug-I | 1984 |
Methylphenidate, apomorphine, THIP, and diazepam in monkeys: dopamine-GABA behavior related to psychoses and tardive dyskinesia.
Topics: Animals; Apomorphine; Chlorocebus aethiops; Diazepam; Dopamine; Drug Interactions; Dyskinesia, Drug- | 1984 |
An analysis of the cortical and striatal involvement in dyskinesia induced in rats by intracerebral injection of GABA-transaminase inhibitors and picrotoxin.
Topics: 4-Aminobutyrate Transaminase; Administration, Topical; Animals; Brain; Cerebral Cortex; Corpus Stria | 1980 |
SL76002 - effect on gamma-aminobutyric acid and dopamine in animals treated chronically with haloperidol.
Topics: Animals; Brain Chemistry; Corpus Striatum; Dopamine; Dyskinesia, Drug-Induced; Frontal Lobe; gamma-A | 1983 |
Symptomatic treatment of tardive dyskinesia: a word of caution.
Topics: Animals; Brain; Dyskinesia, Drug-Induced; gamma-Aminobutyric Acid; Haplorhini; Humans; Levodopa; Mus | 1981 |
State-related cyclical dyskinesias in manic-depressive illness.
Topics: Adult; Bipolar Disorder; Dyskinesia, Drug-Induced; Female; gamma-Aminobutyric Acid; Humans; Male; Mi | 1982 |
Effect of baclofen and haloperidol on gamma-aminobutyric acid and dopamine systems in an animal model of tardive dyskinesia.
Topics: Animals; Baclofen; Brain Chemistry; Disease Models, Animal; Dopamine; Drug Interactions; Dyskinesia, | 1982 |
Dopaminergic and GABAergic aspects of tardive dyskinesia [proceedings].
Topics: Dyskinesia, Drug-Induced; gamma-Aminobutyric Acid; Humans; Receptors, Dopamine; Sulpiride | 1981 |
Evaluation of the role of cortical GABA in the induction of abnormal involuntary movements in rats.
Topics: 4-Aminobutyrate Transaminase; Administration, Topical; Animals; Cerebral Cortex; Dyskinesia, Drug-In | 1981 |
Pharmacologic studies of tardive dyskinesia.
Topics: Animals; Dopamine; Dyskinesia, Drug-Induced; Extrapyramidal Tracts; gamma-Aminobutyric Acid; Humans; | 1980 |
Tardive dyskinesia: recognition, management, and prevention.
Topics: Dyskinesia, Drug-Induced; gamma-Aminobutyric Acid; Humans; Parasympathomimetics | 1980 |
Suppression of haloperidol-induced oral dyskinesias in rats by vigabatrin.
Topics: 4-Aminobutyrate Transaminase; Animals; Anticonvulsants; Body Weight; Brain; Dyskinesia, Drug-Induced | 1995 |
Tiagabine inhibits haloperidol-induced oral dyskinesias in rats.
Topics: Animals; Disease Models, Animal; Drug Evaluation, Preclinical; Dyskinesia, Drug-Induced; gamma-Amino | 1994 |
[What is the connection between Parkinson disease and tardive dyskinesia?].
Topics: Animals; Antipsychotic Agents; Deoxyglucose; Dyskinesia, Drug-Induced; gamma-Aminobutyric Acid; Hapl | 1994 |
An animal model for coexisting tardive dyskinesia and tardive parkinsonism: a glutamate hypothesis for tardive dyskinesia.
Topics: Animals; Brain Chemistry; Cebus; Disease Models, Animal; Dyskinesia, Drug-Induced; gamma-Aminobutyri | 1993 |
Dysregulation of striato-nigral GABAergic pathway by chronic haloperidol treatment: the role of dopamine D1 receptor in the substantia nigra pars reticulata on the development of tardive dyskinesia.
Topics: Animals; Corpus Striatum; Dyskinesia, Drug-Induced; gamma-Aminobutyric Acid; Haloperidol; Male; Mast | 1993 |
The substantia innominata complex and the peripeduncular nucleus in orofacial dyskinesia: a pharmacological and anatomical study in cats.
Topics: Animals; Behavior, Animal; Cats; Cholera Toxin; Dyskinesia, Drug-Induced; Face; gamma-Aminobutyric A | 1993 |
Choreoathetotic movements: A possible side effect of gabapentin.
Topics: Acetates; Adult; Amines; Anticonvulsants; Athetosis; Chorea; Cyclohexanecarboxylic Acids; Dyskinesia | 1996 |
Movement disorders associated with the use of gabapentin.
Topics: Acetates; Adult; Amines; Anticonvulsants; Benzodiazepines; Cyclohexanecarboxylic Acids; Dyskinesia, | 1996 |
Gabapentin as a promising treatment for antipsychotic-induced movement disorders in schizoaffective and bipolar patients.
Topics: Acetates; Adult; Amines; Anti-Anxiety Agents; Antipsychotic Agents; Bipolar Disorder; Cyclohexanecar | 1999 |
Noradrenoceptor antagonism with idazoxan improves L-dopa-induced dyskinesias in MPTP monkeys.
Topics: Adrenergic alpha-2 Receptor Antagonists; Adrenergic alpha-Antagonists; Animals; Antiparkinson Agents | 2000 |
Chronic haloperidol-induced alterations in pallidal GABA and striatal D(1)-mediated dopamine turnover as measured by dual probe microdialysis in rats.
Topics: Animals; Corpus Striatum; Dopamine; Dopamine Antagonists; Dyskinesia, Drug-Induced; Female; gamma-Am | 2000 |
Involvement of GABA neurons in allylnitrile-induced dyskinesia.
Topics: Animals; Brain; Dyskinesia, Drug-Induced; gamma-Aminobutyric Acid; Humans; Male; Mice; Mice, Inbred | 2000 |
Differential role of dopamine D1 and D2 receptors in isoniazid-induced vacuous chewing movements.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Anticonvulsants; Antipsychotic | 2000 |
Animal models of tardive dyskinesia--a review.
Topics: Animals; Antipsychotic Agents; Disease Models, Animal; Dyskinesia, Drug-Induced; Free Radicals; gamm | 2001 |
Reversal of reserpine-induced vacuous chewing movements in rats by melatonin: involvement of peripheral benzodiazepine receptors.
Topics: Adrenergic alpha-Antagonists; Adrenergic Uptake Inhibitors; Animals; Antineoplastic Agents; Dose-Res | 2001 |
Quetiapine-related tardive dyskinesia.
Topics: Acetates; Adult; Amines; Anticonvulsants; Antipsychotic Agents; Bipolar Disorder; Cyclohexanecarboxy | 2001 |
Decreased pallidal GABA following reverse microdialysis with clozapine, but not haloperidol.
Topics: Animals; Antipsychotic Agents; Calcium; Clozapine; Dose-Response Relationship, Drug; Down-Regulation | 2001 |
Gabapentin-related dyskinesia.
Topics: Acetates; Adult; Amines; Anti-Anxiety Agents; Anticonvulsants; Cyclohexanecarboxylic Acids; Dyskines | 2001 |
Alleviation of motor hyperactivity and neurochemical deficits by endocannabinoid uptake inhibition in a rat model of Huntington's disease.
Topics: Animals; Arachidonic Acids; Cannabinoid Receptor Modulators; Cannabinoids; Convulsants; Disease Mode | 2002 |
Improvement in tardive dyskinesia after muscimol therapy.
Topics: Adult; Aged; Antipsychotic Agents; Dopamine; Drug Evaluation; Dyskinesia, Drug-Induced; Extrapyramid | 1979 |
[Potential therapeutic activity of GABA-mimetic drugs in neuropsychiatry].
Topics: 4-Aminobutyrate Transaminase; Basal Ganglia Diseases; Bicuculline; Dopamine; Dyskinesia, Drug-Induce | 1979 |
Mass spectrometric identification and selected ion monitoring quantitation of gamma-amino-butyric acid (GABA) in human lumbar cerebrospinal fluid.
Topics: Bipolar Disorder; Chromatography, Gas; Dyskinesia, Drug-Induced; gamma-Aminobutyric Acid; Humans; Hu | 1978 |
Dyskinetic effects of intrastriatally injected GABA-transaminase inhibitors.
Topics: 4-Aminobutyrate Transaminase; Animals; Corpus Striatum; Dose-Response Relationship, Drug; Dyskinesia | 1979 |
[Neurologic adverse manifestations and complications of ambulatory therapy with psychotropic drugs in the late stages].
Topics: Adult; Aged; Antidepressive Agents; Autonomic Nervous System; Basal Ganglia Diseases; Cognition Diso | 1978 |
Evidence for an intrastriatal GABA control on motor activity arising from dopaminergic hyperfuction in the striatum.
Topics: Animals; Apomorphine; Corpus Striatum; Dyskinesia, Drug-Induced; gamma-Aminobutyric Acid; Hydroxydop | 1978 |
The role of GABA in dyskinesias induced by chemical stimulation of the striatum.
Topics: Aminobutyrates; Animals; Bicuculline; Corpus Striatum; Dose-Response Relationship, Drug; Dyskinesia, | 1977 |
Co-administration of progabide inhibits haloperidol-induced oral dyskinesias in rats.
Topics: Administration, Oral; Animals; Disease Models, Animal; Drug Interactions; Dyskinesia, Drug-Induced; | 1992 |
Neuroleptic-induced "painful legs and moving toes" syndrome: successful treatment with clonazepam and baclofen.
Topics: Baclofen; Causalgia; Clonazepam; Dyskinesia, Drug-Induced; Female; gamma-Aminobutyric Acid; Humans; | 1990 |
Anatomically distinct output channels of the caudate nucleus and orofacial dyskinesia: critical role of the subcommissural part of the globus pallidus in oral dyskinesia.
Topics: Animals; Cats; Caudate Nucleus; Disease Models, Animal; Dyskinesia, Drug-Induced; Facial Muscles; ga | 1989 |
Schizophrenia, tardive dyskinesia, and brain GABA.
Topics: Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Brain; Dyskinesia, Drug-Induced; Female; gamma | 1989 |
Saccadic distractibility in schizophrenic patients with tardive dyskinesia.
Topics: Antipsychotic Agents; Dyskinesia, Drug-Induced; Eye Movements; Fixation, Ocular; gamma-Aminobutyric | 1989 |
[Oral dyskinesia in rats after a single administration of haloperidol combined with GABA-linoleamide. A model of dyskinesia in man].
Topics: Animals; Catalepsy; Disease Models, Animal; Drug Synergism; Dyskinesia, Drug-Induced; gamma-Aminobut | 1989 |
[Late dyskinesia: experimental models, paradoxes and deductions].
Topics: Animals; Dyskinesia, Drug-Induced; gamma-Aminobutyric Acid; Haplorhini; Humans; Models, Biological; | 1987 |
Oral movements induced by interference with nigral GABA neurotransmission: relationship to tardive dyskinesias.
Topics: Animals; Bicuculline; Dyskinesia, Drug-Induced; GABA Antagonists; gamma-Aminobutyric Acid; Injection | 1988 |
Neuroleptic drugs and their action on different neuronal pathways.
Topics: Animals; Antipsychotic Agents; Apomorphine; Behavior, Animal; Brain; Corpus Striatum; Dopamine; Dysk | 1985 |
Experimental tardive dyskinesia.
Topics: Animals; Antipsychotic Agents; Brain; Cebus; Corpus Striatum; Disease Models, Animal; Drug Evaluatio | 1985 |
Chemical and structural changes in the brain in patients with movement disorder.
Topics: 3,4-Dihydroxyphenylacetic Acid; Acetylcholine; Antipsychotic Agents; Brain; Choline O-Acetyltransfer | 1985 |
Tardive dyskinesia: nondopaminergic treatment approaches.
Topics: Basal Ganglia; Dyskinesia, Drug-Induced; gamma-Aminobutyric Acid; Humans; Lithium; Neurotransmitter | 1985 |
Pathophysiological mechanisms underlying tardive dyskinesia.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Brain; Dyskinesia, Drug-Induced; gamma-Aminobutyric Ac | 1985 |
Clinical and biochemical effects of calcium-hopantenate on neuroleptics-induced tardive dyskinesia.
Topics: Adult; Antipsychotic Agents; Dyskinesia, Drug-Induced; gamma-Aminobutyric Acid; Humans; Male; Middle | 1985 |
Tardive dyskinesia: a role for the endogenous opioid system.
Topics: Animals; Antipsychotic Agents; Corpus Striatum; Dopamine; Dyskinesia, Drug-Induced; Endorphins; gamm | 1986 |
Neuroleptic-induced oral dyskinesias: effects of progabide and lack of correlation with regional changes in glutamic acid decarboxylase and choline acetyltransferase activities.
Topics: Animals; Anticonvulsants; Antipsychotic Agents; Brain; Choline O-Acetyltransferase; Dyskinesia, Drug | 1987 |
GABA agonists in cebus monkeys with neuroleptic-induced persistent dyskinesias.
Topics: 4-Aminobutyrate Transaminase; Alkynes; Aminocaproates; Animals; Antipsychotic Agents; Cebus; Dyskine | 1988 |
[The electrophysiological approach to tardive dyskinesias].
Topics: Diagnosis, Differential; Dopamine Agents; Dyskinesia, Drug-Induced; Electromyography; gamma-Aminobut | 1988 |
GABA dysfunction in the pathophysiology of tardive dyskinesia.
Topics: Brain; Dyskinesia, Drug-Induced; gamma-Aminobutyric Acid; Humans; Neural Pathways; Neurons; Receptor | 1985 |
New aspects on the role of dopamine, acetylcholine, and GABA in the development of tardive dyskinesia.
Topics: Acetylcholine; Animals; Cerebral Cortex; Corpus Striatum; Dopamine; Dyskinesia, Drug-Induced; gamma- | 1985 |
3-Mercaptopropionic acid administration into the caudate-putamen of the rat provokes dyskinesia.
Topics: 3-Mercaptopropionic Acid; Animals; Caudate Nucleus; Dyskinesia, Drug-Induced; gamma-Aminobutyric Aci | 1988 |
Clinical and biochemical effects of gamma-vinyl Gaba in tardive dyskinesia.
Topics: Aged; Aminocaproates; Carnosine; Dyskinesia, Drug-Induced; gamma-Aminobutyric Acid; Humans; Mental D | 1987 |
[Tardive dyskinesia--research results and preventive measures].
Topics: Dyskinesia, Drug-Induced; gamma-Aminobutyric Acid; Humans; Receptors, Dopamine; Research | 1987 |
[Vacuous chewing after haloperidol and GABA-linoleamide administration in the rat].
Topics: Animals; Catalepsy; Dyskinesia, Drug-Induced; gamma-Aminobutyric Acid; Haloperidol; Mastication; Psy | 1986 |
Pathophysiology of tardive dyskinesia.
Topics: Animals; Brain; Cebus; Corpus Striatum; Dyskinesia, Drug-Induced; gamma-Aminobutyric Acid; Glutamate | 1985 |
Gamma-vinyl-GABA treatment of tardive dyskinesia and other movement disorders.
Topics: Adult; Aged; Aminocaproates; Confusion; Dyskinesia, Drug-Induced; Female; gamma-Aminobutyric Acid; H | 1985 |
Possible association between tardive dyskinesia and altered carbohydrate metabolism.
Topics: Adult; Blood Glucose; Dyskinesia, Drug-Induced; Fasting; gamma-Aminobutyric Acid; Humans; Middle Age | 1985 |